RCM
AEON icon

Robinson Capital Management’s AEON Biopharma AEON Stock Holding History

Robinson Capital Management’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-342
Closed -$248K – 297
2022
Q4 		$248K Hold
342
– – 0.13% 150
2022
Q3 		$243K Hold
342
– – 0.19% 135
2022
Q2 		$241K Buy
342
+42
+14% +$29.6K 0.18% 121
2022
Q1 		$211K Hold
300
– – 0.14% 127
2021
Q4 		$210K Buy
300
+155
+107% +$109K 0.13% 91
2021
Q3 		$101K Buy
+145
New +$101K 0.09% 89

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Robinson Capital Management's AEON Position: Q1 2023 in Review

Robinson Capital Management sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 342 shares — an estimated $248K sold.

Robinson Capital Management first reported a position in AEON in Q3 2021 and held it in 6 quarters. The position peaked at $248K in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • Robinson Capital Management reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • Robinson Capital Management sold 342 AEON Biopharma shares in Q1 2023, an estimated $248K.
  • Robinson Capital Management first reported a position in AEON Biopharma in Q3 2021 and held it in 6 quarters.
  • Robinson Capital Management's AEON Biopharma position peaked at $248K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Robinson Capital Management's 13F filing for Q1 2023, filed 10 May 2023.